Skye Bioscience Inc (SKYE)

Currency in USD
0.8193
0.0000(0.00%)
Closed·
0.7854-0.0339(-4.14%)
·
SKYE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.80000.8400
52 wk Range
0.68445.7500
Key Statistics
Prev. Close
2.55
Open
0.8113
Day's Range
0.8-0.84
52 wk Range
0.6844-5.75
Volume
-
Average Vol. (3m)
402.24K
1-Year Change
-73.9076%
Book Value / Share
1.06
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SKYE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.2500
Upside
+906.96%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Skye Bioscience Inc News & Analysis

Show more

Skye Bioscience Inc Company Profile

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Skye Bioscience Inc SWOT Analysis


Financial Outlook
Analyst price targets range from $14 to $15, with Skye's $59.2M cash position supporting operations through Q1 2027 despite current unprofitability
Market Potential
With a growing obesity epidemic, Skye Bioscience targets a substantial market opportunity, competing against established players in the pharmaceutical industry
Safety Edge
Nimacimab's peripherally restricted design aims to avoid neuropsychiatric side effects, a common issue with previous CB1 inhibitors
Obesity Breakthrough
Skye Bioscience's nimacimab shows promise in preclinical trials, potentially revolutionizing weight management with its unique CB1 inhibitor mechanism
Read full SWOT analysis

Skye Bioscience Inc Earnings Call Summary for Q3/2025

  • Skye Bioscience reported Q3 2025 net loss of $12.8M with $35.3M in cash reserves; R&D expenses nearly doubled YoY to $9.4M as the company advances its obesity treatment candidate
  • Nemesimab phase 2A study demonstrated promising weight loss results with no neuropsychiatric side effects when used in combination therapy, positioning it uniquely in the competitive obesity market
  • Company plans to initiate a phase 2B combination study targeting higher monotherapy doses and aims to present data at scientific conferences in 2026
  • CEO Puneet Dhillon highlighted the 'synergistic efficacy' of Nemesimab with semaglutide and emphasized pursuing a maintenance therapy indication as a strategic priority
  • Despite increased R&D investment, the stock remained stable with management focusing on addressing potential regulatory hurdles and safety concerns at higher doses
Last Updated: 11/10/2025, 05:46 PM
Read Full Transcript

Compare SKYE to Peers and Sector

Metrics to compare
SKYE
Peers
Sector
Relationship
P/E Ratio
−0.7x−1.8x−0.5x
PEG Ratio
0.010.120.00
Price / Book
1.1x2.6x2.6x
Price / LTM Sales
-109.5x3.3x
Upside (Analyst Target)
-49.7%45.0%
Fair Value Upside
Unlock0.1%5.1%Unlock

Analyst Ratings

6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 8.2500
(+906.96% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy20.00+2,341.11%-MaintainFeb 03, 2026
Cantor Fitzgerald
Hold2.00+144.11%-MaintainJan 15, 2026
Citizens
Buy4.00+388.22%-MaintainJan 05, 2026
Citizens
Buy4.00+388.22%16.00MaintainOct 06, 2025
Oppenheimer
Buy10.00+1,120.55%17.00MaintainOct 06, 2025

Earnings

Latest Release
Nov 10, 2025
EPS / Forecast
-0.32 / -0.23
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SKYE Income Statement

People Also Watch

0.671
CTSO
-0.15%
2.070
EVTV
-6.33%
23.390
BNAI
+4.19%
0.36
VSEE
+1.53%

FAQ

What Is the Skye Bioscience (SKYE) Stock Price Today?

The Skye Bioscience stock price today is 0.8193

What Stock Exchange Does Skye Bioscience Trade On?

Skye Bioscience is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Skye Bioscience?

The stock symbol for Skye Bioscience is "SKYE."

What Is the Skye Bioscience Market Cap?

As of today, Skye Bioscience market cap is 22.99M.

What Is Skye Bioscience's Earnings Per Share (TTM)?

The Skye Bioscience EPS (TTM) is -1.29.

From a Technical Analysis Perspective, Is SKYE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Skye Bioscience Stock Split?

Skye Bioscience has split 2 times.

How Many Employees Does Skye Bioscience Have?

Skye Bioscience has 16 employees.

What is the current trading status of Skye Bioscience (SKYE)?

As of Feb 10, 2026, Skye Bioscience (SKYE) is trading at a price of 0.8193, with a previous close of 2.5500. The stock has fluctuated within a day range of 0.8000 to 0.8400, while its 52-week range spans from 0.6844 to 5.7500.

What Is Skye Bioscience (SKYE) Price Target According to Analysts?

The average 12-month price target for Skye Bioscience is USD8.2500, with a high estimate of USD20 and a low estimate of USD2. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +906.96% Upside potential.

What Is the SKYE After Hours Price?

SKYE's last after hours stock price is 0.7854, the stock has decreased by -0.0339, or -4.1400%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.